11,181 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by Magnetar Financial LLC

Magnetar Financial LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 11,181 shares of the company’s stock, valued at approximately $263,000.

Other large investors have also recently added to or reduced their stakes in the company. abrdn plc acquired a new stake in Dyne Therapeutics in the fourth quarter valued at $608,000. RA Capital Management L.P. lifted its stake in Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the last quarter. Geode Capital Management LLC lifted its stake in Dyne Therapeutics by 4.8% in the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after acquiring an additional 84,760 shares during the last quarter. State Street Corp lifted its stake in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. Finally, Barclays PLC lifted its stake in Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock valued at $7,446,000 after acquiring an additional 128,246 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Chardan Capital reissued a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.46.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $12.08 on Monday. Dyne Therapeutics, Inc. has a 52 week low of $11.18 and a 52 week high of $47.45. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11. The firm’s 50-day simple moving average is $13.60 and its 200 day simple moving average is $24.14.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 6,237 shares of company stock worth $77,760 over the last ninety days. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.